Half Year 2024 Syncona Ltd Earnings Call Transcript
My name is Chris Hollowood, CEO of Syncona, and I welcome you to our Interim Presentation. Over the last 6 months, we've been focused on executing on strategy against the backdrop of a very challenging market. We reported a small decline in NAV principally because of the write off of the Gyroscope milestone after Novartis' decision to discontinue GT005. We talked about at the full year a rigorous capital allocation policy, which we think is essential to navigate this market. The macroeconomic environment continues to be very challenging for biotech companies both in terms of the cost of the capital, but also the access to that capital. That brings financing risk clearly, but also brings opportunity and we're looking at both. Proactive management of the portfolio is key. We are active managers so our skill set really comes to the fore.
We know clinical data is value even in this market and that is where we're focused and that can be seen because 80% of the capital we've deployed in the first 6 months of this financial year has
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |